Orthocell (ASX: OCC) is stepping up its global game, announcing the first sales of its flagship dental regeneration product, Striate+™, in the high-potential DACH region — Germany, Austria, and Switzerland. This marks a major milestone in the company’s European expansion strategy, executed in partnership with exclusive global distributor BioHorizons.
The DACH region is one of Europe’s largest dental markets, and BioHorizons is already well-embedded here, giving Striate+ a fast track to revenue growth. With a total addressable market of over A$1 billion globally — and around A$285 million in the EU and UK alone — Orthocell is targeting a 20% market share. The strong clinical data backing Striate+ (a 98.6% success rate in post-market studies) and glowing feedback from dental surgeons are helping accelerate adoption.
Striate+, for those unfamiliar, is a resorbable collagen membrane used during dental implant procedures to encourage bone and tissue regeneration. Its ease of use and ability to promote high-quality bone growth has made it a standout among practitioners. That momentum is now translating into global traction.
BioHorizons, one of the world’s leading dental implant distributors, is spearheading Striate+’s push not only through Europe but into other key regions. Brazil is next on the launchpad, with regulatory approval expected within three months. Orthocell also has its sights on further international expansion, with approvals in additional markets underway.
Importantly, the company is in a strong financial position to fund its growth, with approximately $32 million cash at bank as of late March. That war chest provides plenty of runway to scale up distribution, support market entries, and capture share in what is shaping up to be a highly valuable global opportunity.
With early European sales now ticking over, a well-resourced distributor in place, and expansion into new markets on the horizon, Orthocell appears well positioned to convert clinical success into commercial momentum.
